Sartorius Stedim Biotech posts 9‑month sales of €2.29 bn and 31.3% EBITDA margin, confirms full‑year guidance

Sartorius Stedim Biotech reported 9‑month 2026 sales of €2.289 bn, up 6.5% year‑on‑year, with underlying EBITDA of €716 m and a margin of 31.3%. Net profit rose 26.7% to €277 m and free cash flow increased 58.5% to €264 m. The company reaffirmed its full‑year outlook, expecting operational sales growth of 6‑10% and an EBITDA margin slightly above 31%.

The company’s confirmation of guidance signals that the strong operating performance is expected to continue, supporting cash‑flow generation and balance‑sheet strength for investors. The higher free‑cash‑flow and improved net‑debt‑to‑EBITDA ratio enhance financial flexibility, according to the earnings‑call commentary.

Sources